Exelixis Stock Surges 50% in a Year: Is There Room for Further Growth?

Shares of Exelixis, Inc. (EXEL) have surged 50% in a year against the industry’s decline of 16.1%. The stock has also outperformed the sector and the S&P 500 Index in this timeframe.The company's stellar performance can be attributed to the strong growth of its lead drug, Cabometyx, raised guidance and encouraging pipeline progress.EXEL Outperforms Industry, Sector & S&P 500Image Source: Zacks Investment ResearchCabometyx Boosts EXELCabometyx maintained its status as the leading tyrosine kinase inhibitor (T ...